New insider activity at Insmed ( (INSM) ) has taken place on November 18, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In recent transactions involving Insmed stock, Director Leo Lee sold 75,000 shares, amounting to a total of $14,692,249. Meanwhile, Director Elizabeth M. Anderson sold 10,000 shares, with the sale valued at $1,958,700.
Recent Updates on INSM stock
Insmed’s recent developments have been marked by a successful Q3 earnings call, highlighting the strong launch of BRINSUPRI with $28 million in net sales and ARIKAYCE’s record revenue quarter. The company raised its 2025 revenue guidance for ARIKAYCE, reflecting its strong market presence. Regulatory progress for brensocatib in the EU and a robust pipeline with upcoming clinical trials for TPIP indicate potential future growth. However, challenges such as inventory stocking and market access uncertainties for BRINSUPRI were noted. Analysts have adjusted price targets, influenced by the successful launch of BRINSUPRI, confidence in the management team, and the company’s evolution into a diversified respiratory-focused platform. These factors, combined with financial strength and a strategic focus on pipeline development, are driving positive sentiment and expectations for Insmed’s continued momentum.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. While technical analysis shows strong momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh heavily. The positive sentiment from the earnings call is not factored into the overall score due to its exclusion from the weighted calculation.
To see Spark’s full report on INSM stock, click here.
More about Insmed
YTD Price Performance: 182.20%
Average Trading Volume: 2,161,435
Technical Sentiment Signal: Buy
Current Market Cap: $41.21B